LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

170.88 1.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

166.35

Máximo

171.71

Indicadores-chave

By Trading Economics

Rendimento

2.9M

56M

Vendas

-27M

1B

P/E

Médio do Setor

592.3

106.172

EPS

2.43

Margem de lucro

5.529

Funcionários

18,700

EBITDA

-23M

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+14.97% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-793M

8B

Abertura anterior

168.93

Fecho anterior

170.88

Sentimento de Notícias

By Acuity

50%

50%

151 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de nov. de 2025, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

BHP Abandons Bid for Anglo American Following New Talks

23 de nov. de 2025, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

23 de nov. de 2025, 22:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

23 de nov. de 2025, 19:00 UTC

Ganhos

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

23 de nov. de 2025, 00:50 UTC

Ganhos

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

22 de nov. de 2025, 10:30 UTC

Ganhos

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 de nov. de 2025, 10:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 de nov. de 2025, 09:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

21 de nov. de 2025, 22:42 UTC

Conversa de Mercado

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

21 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

21 de nov. de 2025, 21:47 UTC

Conversa de Mercado

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 de nov. de 2025, 21:43 UTC

Conversa de Mercado

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 de nov. de 2025, 20:18 UTC

Conversa de Mercado

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 de nov. de 2025, 20:14 UTC

Conversa de Mercado

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 de nov. de 2025, 19:48 UTC

Conversa de Mercado

Precious Metals Fall for the Week -- Market Talk

21 de nov. de 2025, 19:44 UTC

Ganhos

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 de nov. de 2025, 19:37 UTC

Conversa de Mercado

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 de nov. de 2025, 19:27 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

21 de nov. de 2025, 19:27 UTC

Conversa de Mercado
Ganhos

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 de nov. de 2025, 19:20 UTC

Conversa de Mercado

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 de nov. de 2025, 18:44 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 de nov. de 2025, 18:37 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 de nov. de 2025, 18:34 UTC

Conversa de Mercado
Ganhos

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 de nov. de 2025, 18:28 UTC

Ganhos

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 de nov. de 2025, 18:03 UTC

Conversa de Mercado

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 de nov. de 2025, 17:24 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de nov. de 2025, 17:24 UTC

Conversa de Mercado

Intuit Seen on Path to Increase Growth -- Market Talk

21 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

21 de nov. de 2025, 17:05 UTC

Conversa de Mercado

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

14.97% parte superior

Previsão para 12 meses

Média 192.73 USD  14.97%

Máximo 225 USD

Mínimo 165 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

7

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

151 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat